Heterologous immunization with BNT162b2 followed by mRNA-1273 in dialysis patients

• Verfasst von: Kohmer, Niko [VerfasserIn]
• Verfasst von: Rabenau, Holger F [VerfasserIn]
• Verfasst von: Ciesek, Sandra [VerfasserIn]
• Verfasst von: Krämer, Bernhard [VerfasserIn]
• Verfasst von: Göttmann, Uwe [VerfasserIn]
• Verfasst von: Keller, Christine [VerfasserIn]
• Verfasst von: Rose, Daniela [VerfasserIn]
• Verfasst von: Blume, Carsten [VerfasserIn]
• Verfasst von: Thomas, Michael [VerfasserIn]
• Verfasst von: Lammert, Alexander [VerfasserIn]
• Verfasst von: Lammert, Anne [VerfasserIn]
• Titel: Heterologous immunization with BNT162b2 followed by mRNA-1273 in dialysis patients
• Titelzusatz: seroconversion and presence of neutralizing antibodies
• Verf.angabe: Niko Kohmer, Holger F. Rabenau, Sandra Ciesek, Bernhard K. Krämer, Uwe Göttmann, Christine Keller, Daniela Rose, Carsten Blume, Michael Thomas, Alexander Lammert and Anne Lammert
• E-Jahr: 2022
• Jahr: 31 January 2022
• Umfang: 8 S.
• Fussnoten: Gesehen am 26.02.2024
• Titel Quelle: Enthalten in: Nephrology, dialysis, transplantation
• Ort Quelle: Oxford : Oxford Univ. Press, 1986
• Jahr Quelle: 2022
• Band/Heft Quelle: 37(2022), 6 vom: Juni, Seite 1132-1139
• ISSN Quelle: 1460-2385
• DOI: doi:10.1093/ndt/gfac018
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1881575683

Abstract

The vital renal replacement therapy makes it impossible for dialysis patients to distance themselves socially. This results in a high risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and developing coronavuris disease 2019, with excess mortality due to disease burden and immunosuppression. We determined the efficacy of a 100-µg booster of mRNA-1273 (Moderna, Cambridge, MA, USA) 6 months after two doses of BNT162b2 (BioNTech/Pfizer, Mainz, Germany/New York, USA) in 194 SARS-CoV-2-naïve dialysis patients.Anti-SARS-CoV-2 spike antibodies were measured with the Elecsys Anti-SARS-CoV-2 S assay (Roche Diagnostics, Mannheim, Germany) 4 and 10-12 weeks after two doses of BNT162b2 as well as 4 weeks after the mRNA-1273 booster. The presence of neutralizing antibodies was measured by the SARS-CoV-2 Surrogate Virus Neutralization Test (GenScript Biotech, Piscataway, NJ, USA). Two different cut-offs for positivity were used, one according to the manufacturer's specifications and one correlating with positivity in a plaque reduction neutralization test (PRNT). Receiver operating characteristics analyses were performed to match the anti-SARS-CoV-2 spike antibody cut-offs with the cut-offs in the surrogate neutralization assay accordingly.Any level of immunoreactivity determined by the anti-SARS-CoV-2 spike antibody assay was found in 87.3% (n = 144/165) and 90.6% (n = 164/181) of patients 4 and 10-12 weeks, respectively, after two doses of BNT162b2. This was reduced to 68.5% or 60.6% 4 weeks and 51.7% or 35.4% 10-12 weeks, respectively, when using the ROC cut-offs for neutralizing antibodies in the surrogate neutralization test (manufacturer's cut-off ≥103 U/mL and cut-off correlating with PRNT ≥196 U/mL). Four weeks after the mRNA-1273 booster, the concentration of anti-SARS-CoV-2 spike antibodies increased to 23 119.9 U/mL and to 97.3% for both cut-offs of neutralizing antibodies.Two doses of BNT162b2 followed by one dose of mRNA-1273 within 6 months in patients receiving maintenance dialysis resulted in significant titres of SARS-CoV-2 spike antibodies. While two doses of mRNA vaccine achieved adequate humoral immunity in a minority, the third vaccination boosts the development of virus-neutralizing quantities of SARS-CoV-2 spike antibodies (against wild-type SARS-CoV-2) in almost all patients.